Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is -51.49% lower on its value in year-to-date trading and has touched a low of $1.01 and a high of $11.91 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZNTL stock was last observed hovering at around $1.50 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $1.47, the stock is 15.75% and 10.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.04 million and changing -2.00% at the moment leaves the stock -41.54% off its SMA200. ZNTL registered -87.11% loss for a year compared to 6-month loss of -59.84%. The firm has a 50-day simple moving average (SMA 50) of $1.3308 and a 200-day simple moving average (SMA200) of $2.514425.
The stock witnessed a 17.60% gain in the last 1 month and extending the period to 3 months gives it a -23.83%, and is 17.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.96% over the week and 4.26% over the month.
Zentalis Pharmaceuticals Inc (ZNTL) has around 166 employees, a market worth around $105.77M and $26.86M in sales. Profit margin for the company is -834.49%. Distance from 52-week low is 45.54% and -87.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-67.11%).
The EPS is expected to grow by 3.75% this year
174.0 institutions hold shares in Zentalis Pharmaceuticals Inc (ZNTL), with institutional investors hold 92.77% of the company’s shares. The shares outstanding are 71.95M, and float is at 55.63M with Short Float at 11.09%. Institutions hold 80.35% of the Float.
The top institutional shareholder in the company is MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 13.96 million shares valued at $$57.1 million. The investor’s holdings represent 19.6509 of the ZNTL Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 8.68 million shares valued at $$35.49 million to account for 12.2139 of the shares outstanding. The other top investors are EVENTIDE ASSET MANAGEMENT, LLC which holds 8.55 million shares representing 12.0325 and valued at over $$34.96 million, while VANGUARD GROUP INC holds 7.96 of the shares totaling 5.65 million with a market value of $$23.13 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
The most recent transaction is an insider purchase by Myers Scott Dunseth, the company’s Director. SEC filings show that Myers Scott Dunseth bought 21,000 shares of the company’s common stock on Apr 30 ’25 at a price of $1.40 per share for a total of $29373.0. Following the purchase, the insider now owns 0.28 million shares.
Zentalis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 06 ’25 that Bruns Ingmar (Chief Medical Officer) bought a total of 20,000 shares of the company’s common stock. The trade occurred on Feb 06 ’25 and was made at $2.28 per share for $45656.0. Following the transaction, the insider now directly holds 36629.0 shares of the ZNTL stock.
Still, SEC filings show that on Feb 11 ’25, Cam Gallagher (Former Director) Proposed Sale 687 shares at an average price of $2.00 for $1374.0. The insider now directly holds shares of Zentalis Pharmaceuticals Inc (ZNTL).
